The standard testing platform established by the Centers for Disease Control and Prevention and the U. S. Department of Health and Human Services (HHS) in response to a recent outbreak of Ebola poses a threat to many others including dengue virus and malaria.

CDC and the CDC Foundation launched the Infectious Diseases Disease at Risk Research and Prevention Laboratory (IDR) Laboratory-Code of Conduct (ODPCN) Platform in 2016 with the goal of rapidly producing standardized testing standards that are ready every year to confirm the existence and () extent of pathogens at risk.

The IDR Laboratory-Code of Conduct part of the CDC National Center for Laboratory Improvement is aimed at quickly responding to national-level outbreaks of infectious diseases and of other infectious diseases that require rapid and refined response.

In its latest analysis published today in The Lancet Microbe IDR Lab carried out the analysis of strain: Ebola virus and malaria parasites and ebolaviruses meaning that the platform requires development of a high-throughput platform capable of handling the strain growth of any given organism.

Led by Paul Childs from the University of Oxford researchers from IDR Laboratory conducted a high throughput data intensive analysis of a dataset comprising over 2500 plasmids from different countries which are associated with proteins or bacterial cells in an organism that can cause disease.

Various strains of Ebola virus and malaria parasites were analyzed with each pathogen tested for morphological characteristics and concentrations of pathogen-specific metabolic products of the infected cells that help the organism grow.

Their findings demonstrate:

These technologies give us more information about our susceptibility to pathogens than standard test results and definitively identify pathogens and pathogens that are highly transmittable said corresponding author Paul Childs also Professor of UNSWs Institute for Microbiology and Infectious Disease.

This also sets the stage for a rapid rigorous and objective way for business public health and other stakeholders to test for pathogens that have been uncovered through the standard practice added study senior author Professor Brett Sutton from the University of New South Wales in Sydney.